MediPharm Labs Corp.
MEDIF
$0.05
-$0.0015-2.91%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.56% | 24.86% | 30.89% | 31.70% | 57.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.56% | 24.86% | 30.89% | 31.70% | 57.30% |
| Cost of Revenue | 12.52% | 24.11% | 4.28% | -20.95% | -0.90% |
| Gross Profit | 12.64% | 26.45% | 134.35% | 3,360.60% | 1,389.91% |
| SG&A Expenses | -17.43% | 3.08% | -9.99% | -2.94% | 11.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -214.41% | -128.34% | -45.45% | -137.78% | -82.07% |
| Total Operating Expenses | -2.47% | 13.18% | -2.87% | -14.16% | 3.36% |
| Operating Income | 50.56% | 21.63% | 59.69% | 71.60% | 50.71% |
| Income Before Tax | 47.34% | 20.92% | 24.96% | 31.41% | 47.28% |
| Income Tax Expenses | -- | -- | -2,940.91% | -4,511.36% | -4,511.36% |
| Earnings from Continuing Operations | 46.28% | 19.27% | 26.62% | 32.77% | 48.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.28% | 19.27% | 26.62% | 32.77% | 48.31% |
| EBIT | 50.56% | 21.63% | 59.69% | 71.60% | 50.71% |
| EBITDA | 59.52% | 29.08% | 70.80% | 81.59% | 57.72% |
| EPS Basic | 48.44% | 29.41% | 39.66% | 51.08% | 62.74% |
| Normalized Basic EPS | 53.68% | 32.17% | 68.05% | 78.01% | 65.04% |
| EPS Diluted | 48.44% | 29.41% | 39.66% | 51.08% | 62.74% |
| Normalized Diluted EPS | 53.68% | 32.17% | 68.05% | 78.01% | 65.04% |
| Average Basic Shares Outstanding | 4.76% | 13.18% | 17.57% | 29.43% | 38.08% |
| Average Diluted Shares Outstanding | 4.76% | 13.18% | 17.57% | 29.43% | 38.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |